Jump to content

Cytosorbents Corporation

From Wikipedia, the free encyclopedia

This is an old revision of this page, as edited by The Christopher (talk | contribs) at 17:18, 5 May 2016. The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.

Cytosorbents Corporation
NasdaqCTSO
IndustryCritical care
Headquarters
Monmouth Junction, New Jersey
,
USA
ProductsCytoSorb
Number of employees
52

CytoSorbents is a publicly traded company (NasdaqCM: CTSO) located in Monmouth Junction, New Jersey.[1][2][3] Cytosorbents has created a blood purification technology based on biocompatible, highly porous polymer beads that act like sponges in an attempt to remove harmful substances from the blood.[4][5]

CytoSorb, the Company's first product to market, received its CE mark approval in 2011.[6][7]

CytoSorbents was awarded a $3.8 million contract by Defense Advanced Research Projects Agency (DARPA) for its “Dialysis-Like Therapeutics” program to treat sepsis by removing cytokines and pathogen-derived toxins.[8] The US Army awarded the Company a $1.15 million small-business innovation research contract to evaluate the technology in burn and trauma.[9]

References

  1. ^ "CTSO: Summary for CYTOSORBENTS COR- Yahoo! Finance". YAHOO Finance. Retrieved 9 April 2014.
  2. ^ "CTSO stock quote – Cytosorbents Corporation stock price – NASDAQ.com". NASDAQ. Retrieved 9 April 2014.
  3. ^ "CTSO SEC Filings". YAHOO. Retrieved 9 April 2014.
  4. ^ Baum, Stephanie. "Blood purification device for ICU patients seeks to control cytokine storm". Med City News. Retrieved 2013-05-24.
  5. ^ "Septic shock secondary to β-hemolytic streptococcus-induced necrotizing fasciitis treated with a novel cytokine adsorption therapy". The International Journal of Artificial Organs. Retrieved 6 May 2014.
  6. ^ Crutcher, Patrick. "Closer Look: CytoSorbents' Surprise CE Mark Approval". BioMed Reports. Retrieved 4/1/11. {{cite web}}: Check date values in: |accessdate= (help)
  7. ^ "With EU Regulatory Approval Gained CytoSorbents Corporation (OTCBB: CTSO) One Step Closer to Goal of FDA Regulatory Approval". OTC Equity. Retrieved 9 April 2014.
  8. ^ "DARPA Dialysis-Like-Therapeutic Program Awards $3.8M to CytoSorbents". Global BioDefense. Retrieved 9 April 2014.
  9. ^ "CTSO Awarded Ph II U.S. Army Grant". Zacks. Retrieved 9 April 2014.